SAGE Therapeutics (SAGE) Tops Q4 EPS by 4c

SAGE Therapeutics (NASDAQ: SAGE) reported Q4 EPS of ($2.12), $0.04 better than the analyst estimate of ($2.16). Revenue for the quarter came in at $1.64 million versus the consensus estimate of $1.97 million.

For earnings history and earnings-related data on SAGE Therapeutics (SAGE) click here.

You May Also Be Interested In

• Are we witnessing a fundamental or speculative rally in the S&P 500?
• Morgan Stanley backs Yum Brands, cuts Chipotle rating as growth outlook diverges
• IDT Corp. (IDT) Tops Q3 EPS by 2c; offer guidance